There were 125 press releases posted in the last 24 hours and 425,898 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
TG Therapeutics, Inc. Announces Presentation of Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image